Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne Muscular Dystrophy
Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne Muscular Dystrophy
The objective of this study was to estimate the comparative effectiveness of bisphosphonate therapy on bone mineral density (BMD) in patients with corticosteroid-treated Duchenne muscular dystrophy (DMD). A retrospective, comparative effectiveness study evaluating changes in BMD and fragility fractures in patients with DMD presenting to British Columbia Children’s Hospital from 1989 to 2017 was conducted. Marginal structural generalized estimating equation models weighted by stabilized inverse-probability of treatment weights were used to estimate the comparative effectiveness of therapy on BMD. Of those treated with bisphosphonates (N = 38), 7 (18.4%), 17 (44.7%), and 14 (36.8%) cases were treated with pamidronate, zoledronic acid, or a combination of both, respectively, while 36 cases of DMD were untreated. Mean age of bisphosphonate initiation was 9.2 (SD 2.7) years. Mean fragility fractures declined from 3.5 to 1.0 following bisphosphonate therapy. Compared to the treated group, the untreated group had an additional 0.63-SD decrease (95% confidence interval [CI]: −1.18, −0.08, P = .026) in total BMD and an additional 1.04-SD decrease (95% CI: −1.74, −0.34; P = .004) in the left hip BMD, but the change in lumbar spine BMD (0.15, 95% CI: −0.36, 0.66; P = .57) was not significant. Bisphosphonate therapy may slow the decline in BMD in boys with corticosteroid-treated DMD compared to untreated counterparts. Total number of fragility fractures decreased following bisphosphonate therapy
Ronsley, Rebecca
9f89529d-e75c-424c-83e8-9127b2412f5f
Islam, Nazrul
e5345196-7479-438f-b4f6-c372d2135586
Kang, Mehima
7e040f5c-0d8f-43fb-a93e-4520a79b5217
Nadel, Helen
a3927334-5f3a-4e58-a735-129682b07212
Reilly, Christopher
9e0283d4-ea6c-44be-bd04-251e7839267c
Metzger, Daniel
002d6d64-c10f-4e09-b8cd-a85c8131748b
Selby, Kathryn
7862ba51-970d-4475-b107-0aca32733fac
Panagiotopoulos, Constadina
72de7825-15ff-43c6-b423-8a09e2181291
6 December 2020
Ronsley, Rebecca
9f89529d-e75c-424c-83e8-9127b2412f5f
Islam, Nazrul
e5345196-7479-438f-b4f6-c372d2135586
Kang, Mehima
7e040f5c-0d8f-43fb-a93e-4520a79b5217
Nadel, Helen
a3927334-5f3a-4e58-a735-129682b07212
Reilly, Christopher
9e0283d4-ea6c-44be-bd04-251e7839267c
Metzger, Daniel
002d6d64-c10f-4e09-b8cd-a85c8131748b
Selby, Kathryn
7862ba51-970d-4475-b107-0aca32733fac
Panagiotopoulos, Constadina
72de7825-15ff-43c6-b423-8a09e2181291
Ronsley, Rebecca, Islam, Nazrul, Kang, Mehima, Nadel, Helen, Reilly, Christopher, Metzger, Daniel, Selby, Kathryn and Panagiotopoulos, Constadina
(2020)
Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne Muscular Dystrophy.
Clinical Medicine Insights: Endocrinology and Diabetes, 13 (1), [1179551420972400].
(doi:10.1177/1179551420972400).
Abstract
The objective of this study was to estimate the comparative effectiveness of bisphosphonate therapy on bone mineral density (BMD) in patients with corticosteroid-treated Duchenne muscular dystrophy (DMD). A retrospective, comparative effectiveness study evaluating changes in BMD and fragility fractures in patients with DMD presenting to British Columbia Children’s Hospital from 1989 to 2017 was conducted. Marginal structural generalized estimating equation models weighted by stabilized inverse-probability of treatment weights were used to estimate the comparative effectiveness of therapy on BMD. Of those treated with bisphosphonates (N = 38), 7 (18.4%), 17 (44.7%), and 14 (36.8%) cases were treated with pamidronate, zoledronic acid, or a combination of both, respectively, while 36 cases of DMD were untreated. Mean age of bisphosphonate initiation was 9.2 (SD 2.7) years. Mean fragility fractures declined from 3.5 to 1.0 following bisphosphonate therapy. Compared to the treated group, the untreated group had an additional 0.63-SD decrease (95% confidence interval [CI]: −1.18, −0.08, P = .026) in total BMD and an additional 1.04-SD decrease (95% CI: −1.74, −0.34; P = .004) in the left hip BMD, but the change in lumbar spine BMD (0.15, 95% CI: −0.36, 0.66; P = .57) was not significant. Bisphosphonate therapy may slow the decline in BMD in boys with corticosteroid-treated DMD compared to untreated counterparts. Total number of fragility fractures decreased following bisphosphonate therapy
This record has no associated files available for download.
More information
Published date: 6 December 2020
Additional Information:
© The Author(s) 2020
Identifiers
Local EPrints ID: 471615
URI: http://eprints.soton.ac.uk/id/eprint/471615
PURE UUID: de72b48b-8749-4637-9281-16f2479e654c
Catalogue record
Date deposited: 14 Nov 2022 18:15
Last modified: 17 Mar 2024 04:15
Export record
Altmetrics
Contributors
Author:
Rebecca Ronsley
Author:
Nazrul Islam
Author:
Mehima Kang
Author:
Helen Nadel
Author:
Christopher Reilly
Author:
Daniel Metzger
Author:
Kathryn Selby
Author:
Constadina Panagiotopoulos
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics